TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06266481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical dexamethasone
Description: Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% lidocaine was sprayed over the tube for the second group
Description: Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
Study: NCT05487612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Invasive Extracorporeal Circulation
Description: Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cardiopulmonary bypass
Description: Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
Study: NCT05280340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
Study: NCT05324293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMI-115
Description: Once Every 2 weeks, subcutaneously injection
Study: NCT06384079

Intervention type: PROCEDURE
Intervention: Antegrade and retrograde pyelogram
Description: Participation in the study will guarantee that participants will receive this procedure.
Study: NCT05656859

Intervention type: BEHAVIORAL
Intervention: Single group
Description: Survey
Study: NCT04997486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Participants will be asked consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Participants will be asked consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting).
Study: NCT06002620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CSB+
Description: standard care

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CSB+
Description: standard care

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched nutrition food (CEF)
Description: enriched cricket flour at 20%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched nutrition food (CEF)
Description: enriched cricket flour at 20%

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: regular videos, sms reminders and face to face interaction

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined nutrition and education
Description: combined enriched cricket flour and nutrition education
Study: NCT06002412

Intervention type: OTHER
Intervention: Image quality control
Description: The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.

Intervention type: OTHER
Intervention: Image quality control
Description: The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.

Intervention type: OTHER
Intervention: Image quality control
Description: The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.

Intervention type: OTHER
Intervention: Image quality control
Description: The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.
Study: NCT04997317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
Description: 177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
Description: 177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4
Description: 177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4
Description: 177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTA-JR11 (Phase I/II)
Description: In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
Study: NCT05811442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50561 high dose
Description: study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50561 low dose
Description: study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug
Study: NCT05638256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
Study: NCT05009875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food SBD111
Description: Two capsules administered twice daily with morning and evening meals for 52 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules administered twice daily with morning and evening meals for 52 weeks
Study: NCT06179199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOOMA™ tDCS™
Description: The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SOOMA™ tDCS™
Description: The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes
Study: NCT04985604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Tovorafenib tablet for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Tovorafenib tablet for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib capsule for oral use.
Study: NCT05133297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018
Description: Oral tablets administered at dose1 BID daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018
Description: Oral tablets administered at dose2 BID daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018
Description: Oral tablets administered at dose3 BID daily for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Oral tablets administered at 5 mg BID daily for 24 weeks.
Study: NCT04762511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lower dose formulation of HSV vaccine (GSK4108771A)
Description: 2 doses of the lower dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose formulation of HSV vaccine (GSK4108771A)
Description: 2 doses of the low dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
Study: NCT05378971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide, 2mg/d, d1-21; treatment cycles every 28days
Study: NCT04641377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention plus health education
Description: The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
Study: NCT05601154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest Cavity Protection toothpaste
Description: Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
Study: NCT04762511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose formulation of HSV vaccine (GSK4108771A)
Description: 2 doses of the medium dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose formulation of HSV vaccine (GSK4108771A)
Description: 2 doses of the high dose formulation of the HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: 2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: 2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: 2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: 2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
Study: NCT05601154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse
Description: Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate PreviDent 5000+ toothpaste
Description: Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse
Description: Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
Study: NCT05408377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MA group
Description: We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SA group
Description: The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
Study: NCT05672381

Intervention type: PROCEDURE
Intervention: Lower extremity and/or upper extremity surgery
Description: Lower extremity and/or upper extremity surgery

Intervention type: PROCEDURE
Intervention: Lower extremity and/or upper extremity surgery
Description: Lower extremity and/or upper extremity surgery
Study: NCT06159361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance targeted exercises
Description: 6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
Study: NCT05507541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontorpacept
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT05236556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best practice advisory (BPA)
Description: For patients who are not on oral anticoagulation (AC) but have elevated stroke risk, the practice advisory will fire, which is to say it will be active in the providers workflow during outpatient encounters with a patient's primary care provider (PCP) or cardiology provider.
Study: NCT06399666

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling
Study: NCT05595837

Intervention type: OTHER
Intervention: Standard organ transplant
Description: Standard organ transplant procedures and follow up care

Intervention type: OTHER
Intervention: Standard organ transplant
Description: Standard organ transplant procedures and follow up care
Study: NCT05514548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-202
Description: INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-202
Description: INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Matching size and number of tablets
Study: NCT05988645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiWEndo System
Description: All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant.~At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo).~In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time.
Study: NCT06433999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Description: Oral Brepocitinib PO QD
Study: NCT06569212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol Dosing:~Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria
Study: NCT04223115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitalized CBT with phone coaching
Description: Digitally delivered CBT intervention with weekly phone coaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation about depression
Description: Psychoeducational material about depression in a digitalized form
Study: NCT06219525

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Higher dose of enteral zinc
Description: Higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard dose of enteral zinc
Description: Standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was discontinued at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
Study: NCT05795166

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT05824650

Intervention type: OTHER
Intervention: Observational
Description: Individuals will be evaluated observationally in a 45-minute period in one day.

Intervention type: OTHER
Intervention: Observational
Description: Individuals will be evaluated observationally in a 45-minute period in one day.